Plant · Scientific monograph
Glycyrrhiza glabra
Licorice Root / Common Liquorice
For educational and scientific research only. Not medical advice. Independently verify claims against the cited primary sources. Consult a qualified healthcare professional before using any plant or fungal preparation.
Research areas: Anti-inflammatory Research, GI Health Research, Hepatoprotection Research, Endocrine Research
Research overview
Historical use
Glycyrrhiza glabra (licorice root) is one of the most ancient medicinal plants on record, documented in Assyrian herbal manuscripts dating to 2100 BCE. In traditional Chinese medicine (gan cao), it functions as a harmonizing herb included in the majority of classical formulas — used to moderate the effects of other herbs, treat cough, sore throat, peptic ulcers, and Addison-like states. Ayurvedic medicine (yashtimadhu) prescribed it for gastric ulcers, respiratory inflammation, aphonia, and as a rejuvenative tonic. European herbalists from Dioscorides onward used the root for dry cough, bronchitis, and gastric irritation. The sweet taste (30–50 times sweeter than sucrose due to glycyrrhizin) made it commercially significant both as a flavouring and medicine.
Modern research context
Note: This monograph covers Glycyrrhiza glabra — the European and Western pharmacopoeia standard species. Some cited studies, particularly those using the Chinese name gan cao, may involve Glycyrrhiza uralensis (Chinese licorice) — a related but distinct species with a partially overlapping phytochemical profile. Evidence from G. uralensis cannot be assumed to apply directly to G. glabra preparations. Glycyrrhiza glabra has documented pharmacological activities across several systems. For gastrointestinal health, carbenoxolone (a synthetic derivative of glycyrrhizinic acid) was a licensed treatment for peptic ulcers before proton pump inhibitors, with Level B clinical evidence for mucosal cytoprotection. Deglycyrrhizinated licorice (DGL) preparations remove glycyrrhizin to eliminate pseudoaldosteronism risk, and RCT evidence supports DGL for dyspepsia and peptic ulcer symptom relief. Hepatoprotective effects via glycyrrhizin are established in Japanese clinical practice (intravenous glycyrrhizin/SNMC is licensed in Japan for chronic hepatitis). Anti-inflammatory effects are well-characterised, mediated through NF-κB and COX inhibition. Estrogen-receptor modulatory activity via glabridin has been investigated for menopausal symptoms in preliminary in vitro and observational studies; clinical RCT evidence for menopausal symptom relief from oral Glycyrrhiza preparations remains limited [primary source for glabridin oestrogenic activity to be identified and added to cited_references]. Research into glycyrrhizin for PCOS-related androgen excess shows emerging evidence [5].
Adverse effects
Pseudoaldosteronism is the major clinical concern with regular high-dose or prolonged licorice consumption: glycyrrhizin inhibits 11β-HSD2, preventing cortisol-to-cortisone conversion in the kidney, causing sodium retention, hypertension, hypokalaemia, and oedema [1]. This is dose- and duration-dependent; the European Medicines Agency considers >100 mg glycyrrhizin/day for prolonged periods to be of concern. Symptoms resolve on discontinuation. Hypertension, peripheral oedema, and hypokalaemic myopathy are the clinical presentations. DGL preparations substantially reduce this risk. Other adverse effects include headache, fatigue, and menstrual irregularities.
Contraindications
Hypertension — glycyrrhizin-containing preparations contraindicated; DGL may be used with caution. Hypokalaemia or conditions predisposing to it (diuretic use, renal tubular acidosis). Heart failure or oedematous states. Renal impairment — sodium and fluid retention risk. Hepatic cirrhosis. Concurrent corticosteroid use — additive hypokalaemia. Pregnancy — uterotonic and pseudoaldosteronism risk; avoid medicinal doses. Drugs sensitive to hypokalaemia (digoxin toxicity risk increased). Oral contraceptives and antihypertensives — pharmacodynamic interactions.
Clinical and phytochemical data
Used part
Root and rhizome (dried, as aqueous extract, ethanolic extract, or DGL — deglycyrrhizinated licorice). Glycyrrhizin content varies: standardized extracts specify glycyrrhizin %; DGL preparations contain <3% glycyrrhizin.
Primary active compounds
Glycyrrhizin / glycyrrhizinic acid (triterpenoid saponin, ~4–25% of root dry weight) — primary active; 11β-HSD2 inhibitor
Glycyrrhizinic acid (aglycone of glycyrrhizin, also called 18β-glycyrrhetic acid)
Glabridin (isoflavonoid, ~0.1%) — estrogenic, melanogenesis-inhibiting, anti-inflammatory
Liquiritigenin and isoliquiritigenin (chalcone/flavanone) — estrogenic, anticancer in vitro
Licochalcone A, B (chalcones) — anti-inflammatory, antimicrobial
Glycyrrhizol A, glabrol (phytosterol-related compounds)
Polysaccharides (immunomodulatory)
Mechanism of action
Glycyrrhizin is the principal pharmacologically active compound and acts by potently inhibiting 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) — the enzyme that converts active cortisol to inactive cortisone in kidney tubules. By blocking this conversion, glycyrrhizin allows cortisol to bind mineralocorticoid receptors, producing pseudoaldosteronism (sodium retention, potassium wasting, hypertension) — the primary safety mechanism [1]. Simultaneously, glycyrrhizin and glycyrrhizinic acid exert anti-inflammatory effects via inhibition of NF-κB, AP-1, and phospholipase A2, reducing arachidonic acid cascade activation and COX-2 expression. Glabridin has demonstrated selective oestrogen receptor binding (ERα/ERβ) in in vitro studies, with tissue-specific oestrogenic activity proposed from cell culture data; clinical RCT confirmation for menopausal or PCOS applications is not established [5]. Antiviral activity is mediated through inhibition of viral membrane fusion and immune stimulation. Hepatoprotective activity in chronic hepatitis involves suppression of inflammatory liver injury via NF-κB inhibition and induction of IL-10.
Pharmacokinetics
Absorption
Glycyrrhizin is poorly absorbed intact from the GI tract (oral bioavailability <1%); it is hydrolyzed by colonic bacterial β-glucuronidase to glycyrrhizinic acid (18β-glycyrrhetic acid), which is absorbed and reaches systemic circulation. Peak plasma concentrations of glycyrrhizinic acid occur 8–24 hours after oral glycyrrhizin ingestion due to this delayed bacterial conversion. Glabridin oral bioavailability is moderate; Tmax approximately 2–3 hours.
Distribution
Glycyrrhizinic acid: extensive plasma protein binding (~95%); distributes to liver and kidney. Enterohepatic recirculation of glycyrrhizinic acid contributes to prolonged systemic exposure. Glabridin distributes to adipose tissue in animal models given its lipophilicity.
Metabolism
Glycyrrhizin → glycyrrhizinic acid (colonic bacterial hydrolysis) → further phase II hepatic conjugation (glucuronides, sulfates) → excretion. Glabridin undergoes CYP3A4-mediated oxidation and phase II conjugation. Glycyrrhizinic acid undergoes enterohepatic circulation — conjugated in liver, excreted in bile, deconjugated in intestine, reabsorbed — producing prolonged effective half-life.
Excretion
Biliary excretion predominates for glycyrrhizinic acid and its conjugates; renal excretion is secondary. Effective t1/2 of glycyrrhizinic acid prolonged by enterohepatic cycling — approximately 10–34 hours. Glabridin: primarily biliary/fecal excretion.
Safety and interactions
Drug interactions
Antihypertensives (all classes): antagonism of blood pressure control via mineralocorticoid effect — clinically significant; may require dose adjustment or discontinuation. Diuretics (thiazides, loop diuretics): additive hypokalaemia — combined hypokalaemia risk; avoid. Digoxin: hypokalaemia increases digoxin toxicity risk — contraindicated with glycyrrhizin-containing preparations in patients on digoxin. Corticosteroids (prednisolone, others): 11β-HSD2 inhibition prolongs corticosteroid half-life and increases mineralocorticoid effect — potentiation of steroid adverse effects. Oral contraceptives: may exacerbate sodium retention and hypertension. Insulin/antidiabetics: glycyrrhizin may affect glucocorticoid metabolism and glucose homeostasis — monitor blood glucose. Warfarin: limited data; caution advised.
Toxicity
The toxicity risk of glycyrrhizin is well-established and dose-dependent. The Lancet documented pseudoaldosteronism with hypertensive crisis, severe hypokalaemia, and paralysis from excessive licorice consumption [1]. The WHO acceptable daily intake for glycyrrhizin is 0.2 mg/kg/day. DGL preparations (<3% glycyrrhizin) substantially reduce systemic mineralocorticoid risk. No hepatotoxicity signal from standardized licorice root in clinical use; hepatoprotective effects are more commonly reported. LD50 data in animals suggests low acute toxicity; chronic mineralocorticoid effects are the primary toxicological concern.
Special precautions
Pregnancy
Medicinal-dose licorice root is not recommended during pregnancy. A Finnish cohort study associated high maternal licorice consumption with lower gestational age, elevated cortisol in offspring, and cognitive effects — attributed to 11β-HSD2 inhibition in the placenta affecting foetal cortisol regulation (primary source: Räikkönen K et al. Finnish cohort studies on maternal licorice consumption — PMID to be verified and added to cited_references). Evidence basis: human observational cohort data and animal experimental data. DGL preparations may carry lower risk but insufficient data to recommend during pregnancy.
Lactation
Glycyrrhizinic acid may be excreted in breast milk. Insufficient clinical safety data for medicinal-dose use during breastfeeding. Not recommended.
Hepatic impairment
Paradoxically, intravenous glycyrrhizin (SNMC) is used therapeutically in Japan for chronic viral hepatitis and liver fibrosis under medical supervision. For oral preparations in patients with hepatic cirrhosis: sodium retention from mineralocorticoid effect worsens portal hypertension and ascites — contraindicated. DGL may be used with hepatic monitoring.
Renal impairment
Glycyrrhizin-containing preparations contraindicated in significant renal impairment — sodium retention, hypokalaemia, and fluid overload exacerbate renal disease. DGL preparations may be used cautiously with monitoring of electrolytes and renal function.
Sources and references
- [1] - Stormer FC, Reistad R, Alexander J, "Glycyrrhizic acid in liquorice — evaluation of health hazard", Food Chem Toxicol, 1993; and van Uum SHM et al., "Licorice and hypertension", Lancet, 2000, PMID: 10675182
- [2] - Rizzato G et al., "Herbal medicine: phytotherapy for respiratory disease", Phytother Res, 2017, PMID: 28685911
- [3] - Omar HR et al., "Licorice abuse: time to send a warning message", Ther Adv Endocrinol Metab, 2012; and systematic review of adverse effects, Phytother Res, 2017, PMID: 28833680
- [4] - CITATION REMOVED: Prior reference (Kupfersztain C et al., Angelica sinensis + Matricaria chamomilla for hot flushes, Maturitas 2014, PMID 25262476) was incorrectly assigned to support the glabridin/oestrogen claim — this paper does not involve Glycyrrhiza glabra. Replacement citation for glabridin oestrogenic activity required (e.g., Tamir S et al. or a validated review of licorice phytoestrogens).
- [5] - Jiang M et al., "Glycyrrhiza species and PCOS", J Ovarian Res, 2024, PMID: 39080737